Proactive Investors - Run By Investors For Investors

Orgenesis gains after announcing venture with TheraCell for cell and gene therapy development

TheraCell, operating in Greece, has developed a patented platform for tissue engineering and cell therapies in the areas of dermatology, chondral defects and chronic kidney injury
People working in a lab
Vered Caplan, CEO of Orgenesis, describes TheraCell as an innovator and pioneer

Orgenesis Inc (NASDAQ:ORGS) rose Thursday after announcing that it has agreed to a joint venture with TheraCell Advanced Biotechnology SA for the clinical development and commercialization of cell and gene therapies.

The joint venture will draw on the companies’ combined technical, regulatory and commercial expertise in Greece, other Balkan countries, Cyprus and Turkey to bring advanced therapy medicinal products to patients, according to Orgenesis.

Shares of Orgenesis climbed 0.9% to $5.65 in Thursday’s Nasdaq trading.

DEEP DIVE: Orgenesis leads the charge at an exciting time for cell therapy

Under a master service agreement, Orgenesis will provide regulatory consultancy services, pre-clinical studies and intellectual property services.

TheraCell is a regenerative-biotechnology company with operations in Greece, where its laboratories and primary facilities are located.

The company focuses on autologous cell therapy and regenerative medicine. It has extensive experience in the isolation, processing and application of adipose-derived stem cells, as well as somatic cells, according to Orgenesis.

It has developed a patented platform for tissue engineering and cell therapies in the areas of dermatology, chondral defects and chronic kidney injury, according to Orgenesis.

“TheraCell is an innovator and pioneer in the fields of cell therapy and regenerative medicine,” Orgenesis CEO Vered Caplan said in a statement, adding that her company is working with TheraCell on a project focused on kidney regeneration. 

Contact Dennis Fitzgerald at [email protected]

View full ORGS profile View Profile

Orgenesis Timeline

Related Articles

antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use